Gastrointestinal Adverse effect with oral bisphophonate Survey

Gastrointestinal Adverse effect with oral bisphophonate Survey - GAP Survey Research

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008422

Enrollment

200

Registered

2012-07-17

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Alendronic acid for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Osteoporotic patients who initiate the first oral bisphosphonate therapy

Exclusion criteria

Exclusion criteria: 1) Patient who has received bisphosphonates. However, after discontinuing these bisphosphonates for six months, it is possible to register. 2) Woman who are in pregnant or who hopes for pregnancy 3) Patient who has serious hepatopathy, renal damage, and cardiac disease 4) Patients judged as improper to participate for the clinical trial by physician in charge

Design outcomes

Primary

Measure	Time frame
Subjective sympotom derived from QOL inquiries at 1 or 3 months after initiation of bisphosphonate therapy.	—

Countries

Japan

Contacts

Public ContactMika Yamauchi

Shimane University Faculty of Medicine Internal Medicine 1

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026